Dr Antonio Passaro is a medical oncologist within the Division of Thoracic Oncology at the European Institute of Oncology in Milan, Italy.
Holding a PhD in molecular medicine with a focus on lung cancer, Dr Passaro’s numerous areas of research in NSCLC encompass topics including predictive biomarkers, targeted therapies, and treatment sequencing. He is heavily involved and interested in investigating the use of targeted agents as monotherapy or in combination therapy, both in the early and advanced stages of disease.
With over 90 publications in NSCLC, he has authored on topics such as EGFR mutation as a mechanism of resistance, the characterisation of common and uncommon mutations in EGFR, and how these variants can be targeted with the use of EGFR TKIs. Dr Passaro has served as Principal or Sub-Investigator in many sponsored and academic trials, spanning a range of novel therapies.
Dr Passaro is a member of the ESMO Council, Chair of the Press & Media Affairs Committee, and a member of the ESMO Lung Cancer Faculty.
EM-87466 - Date of preparation: May 2022